Skip to main content
OpenTrials
Completed

NCT Number: NCT00349180

Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)

This study is performed to confirm the optimal dose for THR (total hip replacement).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Arthroplasty, Replacement, Hip

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Sanofi-Aventis

Tokyo, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients undergoing elective primary THR (total hip replacement) surgery

Exclusion criteria

  • Patient with risk of clinical significant bleeding

Treatment and study plan

Enoxaparin sodium

Drug

Primary outcomes

  1. Incidence of VTE

Secondary outcomes

  1. Incidence of bleeding

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Registry information

Official study title

Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium（RP54563）20mg qd and 20mg Bid for 14 Days in Patients With Total Hip Replacement

Important dates

Study start
2006
First posted
Jul 6, 2006
Registry last updated
Mar 27, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.